Home › Lewy Body Dementia › NCT05590637

Comparing Antipsychotic Medications in LBD Over Time

A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease

Who can join

All ages · All sexes

Inclusion Criteria:

* Patients seen in the neurology clinic at UT Health San Antonio
* Diagnosed with psychosis due to PD or DLB
* Requiring initiation of an antipsychotic medication
* Clinical equipoise between quetiapine and pimavanserin must exist
* The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin

Exclusion Criteria:

* Medical contraindication to either medication
* Caregiver unavailable to complete NPI-Q
* Currently taking an antipsychotic medication
* Prescribing provider unwilling to manage either medication

About the study

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

What is being tested

• Pimavanserin (drug)
• Quetiapine (drug)

Sponsor: The University of Texas Health Science Center at San Antonio · Participants: 94 · Started: Apr 22, 2022

Contact the study team

• Carolyn Paiz, BS · Phone: 210-450-8830

Official record on ClinicalTrials.gov — NCT05590637

Locations in the U.S.

Conditions

• Lewy Body Dementia
• Psychotic Disorders
• Hallucinations

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.